FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__ No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices a $2bn bond offering
26 February 2026
AstraZeneca prices a $2bn bond offering
AstraZeneca PLC ("AstraZeneca") announces that its wholly owned
subsidiary AstraZeneca Finance LLC, priced a three tranche global
bond offering totalling $2bn on 25 February 2026. The offering is
expected to close on 2 March 2026, subject to customary closing
conditions. The transaction, which is a global offering registered
with the U.S. Securities and Exchange Commission ("SEC"), consists
of the following three tranches:
Notes issued by AstraZeneca Finance LLC and fully and
unconditionally guaranteed by AstraZeneca
●
$0.65bn
of fixed rate notes with a coupon of 4.000%, maturing 2 March
2031;
●
$0.60bn
of fixed rate notes with a coupon of 4.300%, maturing 2 March 2033;
and
●
$0.75bn
of fixed rate notes with a coupon of 4.600%,
maturing 2 March 2036.
AstraZeneca expects to use the net proceeds of the offering for
general corporate purposes, which may include the refinancing of
existing indebtedness.
BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC
Securities (USA) Inc. and Mizuho Securities USA LLC acted as
joint book-running managers on the transaction.
The notes will be issued under AstraZeneca's effective shelf
registration statement on Form F-3, which AstraZeneca and
AstraZeneca Finance LLC filed with the SEC on 19 March 2024. The
offering is being made solely by means of the prospectus contained
within that shelf registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting BofA
Securities, Inc. by telephone at +1-800-294-1322; Deutsche
Bank Securities Inc. toll-free at +1-800-503-4611; HSBC Securities
(USA) Inc., by telephone at +1-866-811-8049; or Mizuho Securities
USA LLC, by telephone at +1 866-271-7403. Readers may also download
these documents for free by visiting the Electronic Data Gathering,
Analysis, and Retrieval (EDGAR) system on the SEC website
at www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact AstraZeneca's financial guidance
for 2026.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 26 February 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
